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Case ReportsEarly stenosis of Medtronic Mosaic bioprosthesis in the aortic
positionSheen Peeceeyen, MCh, Christopher Cao, BSc (Med), MBBS, Gary Fermanis, MD, FRACS, and
Con Manganas, MD, FRACS, Sydney, AustraliaThe Medtronic Mosaic valve (Medtronic, Inc, Minneapolis,
Minn) is a third-generation stented porcine bioprosthesis
combining physiologic fixation and a-amino-oleic acid
antimineralization treatment to improve hemodynamic per-
formance and durability.1 Despite encouraging short-term
and midterm clinical results, however, there has been
a heightened interest in the safety and efficacy of this device
after a recent case series study of early valve failure result-
ing from an unknown cause.2 We present here 2 case reports
of early structural valve dysfunction after implantation of
the Mosaic valve in the aortic position.
CLINICAL SUMMARIES
Patient 1
A 74-year-old man with severe aortic insufficiency and
double-vessel coronary artery disease underwent an aortic
valve replacement with a 25-mm Medtronic Mosaic bio-
prosthesis combined with two coronary artery bypass
grafts. His postoperative gradient was 16.5 mm Hg, with
an indexed effective orifice area (EOA) of 0.90 cm2/m2.
The patient had an uneventful recovery and was dis-
charged on a regimen of warfarin for 3 months with a ther-
apeutic international normalized ratio of 2.0 to 3.0.
Subsequently, his anticoagulation regimen was altered to
aspirin alone.
The patient showed marked symptoms 18 months after
surgery. Repeated echocardiography revealed a peak gradi-
ent of 76 mm Hg across the aortic bioprosthesis with re-
stricted leaflet mobility. In view of the severe symptoms
and echocardiographic findings, the patient underwent re-
operation. The original Mosaic valve was explanted and re-
placed with a 27-mm St Jude mechanical valve (St Jude
Medical, Inc, St Paul Minn). Intraoperatively, the leaflets
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pects of the leaflets. Histopathologic examination reported
fibrinoid material on the surfaces of the leaflets. The pa-
tient had an excellent outcome after the second valve im-
plantation and was discharged home after an uneventful
recovery.Patient 2
A 62-year-old woman who presented with severe aortic
stenosis and moderate aortic regurgitation underwent an
aortic valve replacement with a 23-mm Medtronic Mo-
saic valve. She had an indexed EOA of 0.83 cm2/m2. Af-
ter an unremarkable postoperative course, she underwent
routine follow-up with repeated echocardiography at reg-
ular intervals. Three years after the initial surgery, echo-
cardiography demonstrated a mean prosthetic gradient of
13 mm Hg with no significant abnormalities. At 5 postop-
erative years, however, the mean gradient was found to be
32 mm Hg and the peak gradient 59 mm Hg, with evi-
dence of moderate aortic regurgitation. Echocardiogra-
phy also demonstrated a bright echodense lesion at the
tip of the noncoronary cusp, suggestive of calcification.
At the same time, the patient showed a recrudescence
of symptoms and underwent reoperative aortic valve re-
placement with a Carbomedics prosthesis (SORIN
GROUP USA, Inc, Arvada, Colo). This patient was also
discharged home after an uneventful recovery. The ex-
planted Medtronic Mosaic valve was found to be severely
calcified.DISCUSSION
Lawton and colleagues2 reported 4 cases of early steno-
sis from a cohort of 106 patients who underwent aortic
valve replacement with the Mosaic bioprosthesis. The in-
dexed EOA for these patients ranged from 0.76 to 0.89
cm2/m2, and early stenosis was identified 3 to 44 months
after implantation. Lawton and colleagues2 were not able
to determine the pathophysiology of this early valvular
dysfunction but excluded patient–prosthesis mismatch as
a possible cause because the indexed EOA was greater
than 0.75 cm2/m2 in these 4 patients. Jamieson and co-
workers3 responded to this report by highlighting that
only 2 of the 4 patients had undergone implantation of
the Mosaic valves at the reporting center. In addition, after
reviewing the photographic, pathologic, and radiographicrdiovascular Surgery c Volume 143, Number 2 e13
Case Reportsevidence of the explanted valves, they concluded that 2 of
the bioprostheses were thrombosed and that the other 2 had
coagulated blood on the outflow of the cusps and thus
should not be classified as demonstrating structural valve
dysfunction. This view was not shared by Flameng and as-
sociates,4 however, who hypothesized that early stenotic-
type valvular dysfunction in the 4 reported cases was
perhaps related to patient–prosthesis mismatch or turbulent
transvalvular flow. Their definition of moderate patient–
prosthesis mismatch for patients with an indexed EOA of
less than 0.85 has since been challenged by Jamieson
and colleagues.5
We have presented the cases of 2 patients with early ste-
notic valve failure who did not have any evidence of pa-
tient–prosthesis mismatch, and had postoperative indexed
EOAs of 0.90 cm2/m2 and 0.83 cm2/m2. In addition, the ex-
planted valves did not reveal any pannus formation or histo-
logic evidence of thrombosis, although thrombosis could
not be ruled out in the first case on the basis of the available
evidence. Importantly, there was no evidence of subthera-
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mented hypercalcemic syndromes. After detailed patho-
logic examination, it remains unclear what caused the
early valvular dysfunction of the Mosaic bioprostheses in
our patients. In view of our findings, however, we believe
that there is a need for clinical vigilance with regular echo-
cardiographic follow-up in patients who have had implanta-
tion of Mosaic aortic bioprosthetic valves.References
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diovasc Surg. 2010;140:1200-1.Saphenous vein graft bronchopulmonary fistula after coronary artery
bypass grafting presenting as chronic cough and subsequent massive
hemoptysisElizabeth Belcher, MRCP, FRCS, PhD,a Edward Townsend, FRCS,a and Fabio De Robertis, MD,b London,
United KingdomAortocoronary conduit bronchopulmonary fistula is a rare,
potentially lethal complication seen after coronary artery
bypass grafting (CABG). The ideal diagnostic modality in
such cases is not established. We present a case of early-
onset aortocoronary conduit bronchopulmonary fistula
diagnosed by coronary angiography and immediate
noncontrast computed tomography (CT) in a patient with
massive hemoptysis 8 weeks after CABG.CLINICAL SUMMARY
A 75-year-old woman underwent elective CABG. Con-
duits were fashioned from left internal thoracic artery to
left anterior descending coronary artery and long saphenous
vein graft to posterior descending coronary artery. The as-
cending aorta was noted to be thin walled and dilated, mea-
suring 3.6 cm. On removal of the cardioplegia cannula from
the ascending aorta, a complex 2-cm2 tear was noted. Con-
trol of this area was undertaken by fashioning the proximal
aorta–saphenous vein graft anastomosis in an oversized
manner.
At follow-up, the patient was noted to have acquired
a chronic cough. At 8 postoperative weeks, the patient
had sudden significant hemoptysis. Contrast chest CT dem-
onstrated a filling defect in the bronchus intermedius, con-
sistent with hemorrhage, retrosternal fluid collection, and
opacification within the medial portion of the right upper
lobe (Figure 1, A). Rigid bronchoscopy showed large
amounts of blood throughout the tracheobronchial tree but
no active bleeding point. Coronary angiographyery c February 2012
